Mekhail Extension of the Motzer Score predicts metastatic renal cell carcinoma survival, more accurately than the Motzer Score.
To predict metastatic renal cell carcinoma survival, more accurately than the Motzer Score.
Addition of selected points: 0 points 1 point Time from initial diagnosis to systemic treatment <1 year No Yes Prior treatment with radiation No Yes ≥2 sites of metastasis No Yes LDH >1.5× upper limit of normal (Normal: 140 U/L) No Yes Hgb <lower limit of normal (Normal: <12 g/dL (120 g/L)) No Yes Corrected serum calcium >10 mg/dL (3 mmol/L) No Yes Interpretation: Score Risk Median Survival 0-1 Favorable 28 months 2 Intermediate 14 months ≥3 Poor 5 month
1. Mekhail TM, Abou-jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832-41.
OBSERVATION.lab_test-full_blood_count.v1, OBSERVATION.lab_test_serum_calcium.v1, EVALUATION.mekhail_extension_of_the_motzer_score_assessment.v0, OBSERVATION.mekhail_extension_of_the_motzer_score.v0, OBSERVATION.lab_test-ldh.v0